Amgen Outpaces Merck in Dividend Growth and Portfolio Depth
Investors looking for pharmaceutical companies to support their retirement portfolios have a choice between Amgen and Merck. Both companies deliver quarterly dividends, but only one has the portfolio depth to keep growing its payout through patent expirations. Amgen currently pays $2.52 per share, an annualized forward payout of $10.08, giving it a yield of roughly 2.6%. Merck, on the other hand, pays $0.85 quarterly, or $3.40 annualized, with a yield of about 2.29%.
When it comes to raising dividends, Amgen has consistently pushed for 6% increases, while Merck's step-ups have been closer to mid-single-digit ranges. This matters more for income holders who need the payout to outrun inflation. Furthermore, Amgen's steeper trajectory is driven by its 17 billion-dollar products.
The durability of each company against patent expirations also differs. Merck's Keytruda franchise generated $8.4 billion in Q2 2026 sales but will moderate as it reaches peak penetration. The company has a commercial opportunity across more than 20 new products, but its pipeline execution is crucial for success. In contrast, Amgen's income base is broader and more diversified, with 22 products showing double-digit growth and six growth drivers that collectively grew 26% in Q2 2026.
The balance sheet is the caveat, as Amgen carries $57.3 billion in debt at roughly 3.2x EBITDA, higher leverage than Merck's investment-grade profile. However, quarterly free cash flow of $3.5 billion comfortably covers a payout that runs near $1.4 billion per quarter.